Prevalence of genitourinary infection in diabetic patients treated with SGLT 2 inhibitors
Conclusion: We need to counsel the patients before starting SGLT2i regarding possible chance of getting genitourinary infection, proper genital hygiene, drinking plenty of water and consulting the doctor if any symptoms at the earliest.Keywords: Diabetes Complications; SGLT 2 inhibitors; genitourinary infections. (Source: African Health Sciences)
Source: African Health Sciences - April 6, 2023 Category: African Health Authors: Acharya Shrikrishna, Bhat Archana Source Type: research
GSE228911 Canagliflozin impairs T-cell effector function via metabolic suppression in autoimmunity.
Series Type : Expression profiling by arrayOrganism : Homo sapiensThis SuperSeries is composed of the SubSeries listed below. (Source: GEO: Gene Expression Omnibus)
Source: GEO: Gene Expression Omnibus - April 4, 2023 Category: Genetics & Stem Cells Tags: Expression profiling by array Homo sapiens Source Type: research
Glycemic Control and Effects of Canagliflozin in Reducing Albuminuria and eGFR: A Post Hoc Analysis of the CREDENCE Trial
Conclusions The effect of canagliflozin on eGFR slope in patients with type 2 diabetes and CKD was more pronounced in patients with higher baseline HbA1c, due partly to the more rapid decline in kidney function in these individuals.PMID:36999981 | DOI:10.2215/CJN.0000000000000161 (Source: Clinical Journal of the American Society of Nephrology : CJASN)
Source: Clinical Journal of the American Society of Nephrology : CJASN - March 31, 2023 Category: Urology & Nephrology Authors: Sjoukje van der Hoek Niels Jongs Megumi Oshima Brendon L Neuen Jasper Stevens Vlado Perkovic Adeera Levin Kenneth W Mahaffey Carol Pollock Tom Greene David C Wheeler Meg J Jardine Hiddo J L Heerspink Source Type: research
Glycemic Control and Effects of Canagliflozin in Reducing Albuminuria and eGFR: A Post Hoc Analysis of the CREDENCE Trial
Conclusions The effect of canagliflozin on eGFR slope in patients with type 2 diabetes and CKD was more pronounced in patients with higher baseline HbA1c, due partly to the more rapid decline in kidney function in these individuals.PMID:36999981 | DOI:10.2215/CJN.0000000000000161 (Source: Clinical Journal of the American Society of Nephrology : CJASN)
Source: Clinical Journal of the American Society of Nephrology : CJASN - March 31, 2023 Category: Urology & Nephrology Authors: Sjoukje van der Hoek Niels Jongs Megumi Oshima Brendon L Neuen Jasper Stevens Vlado Perkovic Adeera Levin Kenneth W Mahaffey Carol Pollock Tom Greene David C Wheeler Meg J Jardine Hiddo J L Heerspink Source Type: research
Glycemic Control and Effects of Canagliflozin in Reducing Albuminuria and eGFR: A Post Hoc Analysis of the CREDENCE Trial
Conclusions The effect of canagliflozin on eGFR slope in patients with type 2 diabetes and CKD was more pronounced in patients with higher baseline HbA1c, due partly to the more rapid decline in kidney function in these individuals.PMID:36999981 | DOI:10.2215/CJN.0000000000000161 (Source: Clinical Journal of the American Society of Nephrology : CJASN)
Source: Clinical Journal of the American Society of Nephrology : CJASN - March 31, 2023 Category: Urology & Nephrology Authors: Sjoukje van der Hoek Niels Jongs Megumi Oshima Brendon L Neuen Jasper Stevens Vlado Perkovic Adeera Levin Kenneth W Mahaffey Carol Pollock Tom Greene David C Wheeler Meg J Jardine Hiddo J L Heerspink Source Type: research
Glycemic Control and Effects of Canagliflozin in Reducing Albuminuria and eGFR: A Post Hoc Analysis of the CREDENCE Trial
Conclusions The effect of canagliflozin on eGFR slope in patients with type 2 diabetes and CKD was more pronounced in patients with higher baseline HbA1c, due partly to the more rapid decline in kidney function in these individuals.PMID:36999981 | DOI:10.2215/CJN.0000000000000161 (Source: Clinical Journal of the American Society of Nephrology : CJASN)
Source: Clinical Journal of the American Society of Nephrology : CJASN - March 31, 2023 Category: Urology & Nephrology Authors: Sjoukje van der Hoek Niels Jongs Megumi Oshima Brendon L Neuen Jasper Stevens Vlado Perkovic Adeera Levin Kenneth W Mahaffey Carol Pollock Tom Greene David C Wheeler Meg J Jardine Hiddo J L Heerspink Source Type: research
Repurposing Canagliflozin to target brain aging
Aging (Albany NY). 2023 Mar 24;15. doi: 10.18632/aging.204624. Online ahead of print.NO ABSTRACTPMID:36971696 | DOI:10.18632/aging.204624 (Source: Aging)
Source: Aging - March 27, 2023 Category: Biomedical Science Authors: Hashan Jayarathne Wanqing Liu Marianna Sadagurski Source Type: research
Repurposing Canagliflozin to target brain aging
Aging (Albany NY). 2023 Mar 24;15. doi: 10.18632/aging.204624. Online ahead of print.NO ABSTRACTPMID:36971696 | DOI:10.18632/aging.204624 (Source: Aging)
Source: Aging - March 27, 2023 Category: Biomedical Science Authors: Hashan Jayarathne Wanqing Liu Marianna Sadagurski Source Type: research
Systematic review of sodium ‐glucose cotransporter 2 inhibitors: a hopeful prospect in tackling heart failure‐related events
The objective was to systematically review randomized controlled trials (RCTs) assessing the effects of SGLT2 inhibitors, particularly canagliflozin, empagliflozin, dapagliflozin, ertugliflozin, sotagliflozin (dual SGLT inhibitor), and their use in HF. Systematic searches of PubMed/Medline, The Cochrane Central Register of Controlled Trials (CENTRAL), andClinicalTrials.gov databases were performed. There were no restrictions imposed on the date and status of publication; however, there were restrictions on language for the searched studies. A total of 1139 records were identified in the bibliographic searches from both dat...
Source: ESC Heart Failure - March 27, 2023 Category: Cardiology Authors: Buena Aziri,
Edin Begic,
Slobodan Jankovic,
Zorica Mladenovic,
Bojan Stanetic,
Tamara Kovacevic ‐Preradovic,
Amer Iglica,
Aida Mujakovic Tags: Review Source Type: research
Combined treatment with teneligliptin and canagliflozin additively suppresses high-fat diet-induced body weight gain in mice with modulation of lipid metabolism-related gene expression
In this study, we evaluated the effects of combined treatment with a DPP-4 inhibitor, teneligliptin, and an SGLT2 inhibitor, canagliflozin, on the body weight and lipid metabolism in high-fat diet (HFD)-induced obese mice. We found that monotherapy with teneligliptin or canagliflozin showed suppressive effects on high-fat diet-induced body weight gain and reduced inguinal white adipose tissue (iWAT) mass, and combined treatment additively reduced body weight gain and iWAT mass. Teneligliptin significantly increased oxygen consumption during the light phase, and this effect was preserved in the combined treatment. The combi...
Source: European Journal of Pharmacology - March 25, 2023 Category: Drugs & Pharmacology Authors: Satoko Kawarasaki Honami Sawazaki Hiroaki Iijima Haruya Takahashi Wataru Nomura Kazuo Inoue Teruo Kawada Tsuyoshi Goto Source Type: research
Combined treatment with teneligliptin and canagliflozin additively suppresses high-fat diet-induced body weight gain in mice with modulation of lipid metabolism-related gene expression
In this study, we evaluated the effects of combined treatment with a DPP-4 inhibitor, teneligliptin, and an SGLT2 inhibitor, canagliflozin, on the body weight and lipid metabolism in high-fat diet (HFD)-induced obese mice. We found that monotherapy with teneligliptin or canagliflozin showed suppressive effects on high-fat diet-induced body weight gain and reduced inguinal white adipose tissue (iWAT) mass, and combined treatment additively reduced body weight gain and iWAT mass. Teneligliptin significantly increased oxygen consumption during the light phase, and this effect was preserved in the combined treatment. The combi...
Source: European Journal of Pharmacology - March 25, 2023 Category: Drugs & Pharmacology Authors: Satoko Kawarasaki Honami Sawazaki Hiroaki Iijima Haruya Takahashi Wataru Nomura Kazuo Inoue Teruo Kawada Tsuyoshi Goto Source Type: research
Sodium-glucose co-transporter-2 inhibitors increase Klotho in patients with diabetic kidney disease: A clinical and experimental study
Biomed Pharmacother. 2022 Oct;154:113677. doi: 10.1016/j.biopha.2022.113677. Epub 2022 Sep 7.ABSTRACTSodium-glucose co-transporter-2 inhibitors (SGLT2i) provide cardiorenal protection. However, the molecular mechanisms remain poorly understood. We explored the impact of SGLT2i on Klotho, a kidney-derived protein with antiaging, renal-protective and heart-protective properties. A real world prospective observational study addressed the impact of initiating SGLT2i (canagliflozin, dapagliflozin, empagliflozin) or dipeptidyl peptidase-4 inhibitors (DPP4i) in patients with early diabetic kidney disease (DKD). Serum and urinary ...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - March 21, 2023 Category: Drugs & Pharmacology Authors: Carmen Mora-Fern ández Mar ía Dolores Sánchez-Niño Javier Donate-Correa Ernesto Mart ín-Núñez Nayra P érez-Delgado Lara Vali ño-Rivas Beatriz Fern ández-Fernández Alberto Ortiz Juan F Navarro-Gonz ález Source Type: research
Sodium-glucose co-transporter-2 inhibitors increase Klotho in patients with diabetic kidney disease: A clinical and experimental study
Biomed Pharmacother. 2022 Oct;154:113677. doi: 10.1016/j.biopha.2022.113677. Epub 2022 Sep 7.ABSTRACTSodium-glucose co-transporter-2 inhibitors (SGLT2i) provide cardiorenal protection. However, the molecular mechanisms remain poorly understood. We explored the impact of SGLT2i on Klotho, a kidney-derived protein with antiaging, renal-protective and heart-protective properties. A real world prospective observational study addressed the impact of initiating SGLT2i (canagliflozin, dapagliflozin, empagliflozin) or dipeptidyl peptidase-4 inhibitors (DPP4i) in patients with early diabetic kidney disease (DKD). Serum and urinary ...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - March 21, 2023 Category: Drugs & Pharmacology Authors: Carmen Mora-Fern ández Mar ía Dolores Sánchez-Niño Javier Donate-Correa Ernesto Mart ín-Núñez Nayra P érez-Delgado Lara Vali ño-Rivas Beatriz Fern ández-Fernández Alberto Ortiz Juan F Navarro-Gonz ález Source Type: research
Feasibility study to assess canagliflozin distribution and sodium-glucose co-transporter 2 occupancy using [ < sup > 18 < /sup > F]Canagliflozin in patients with type 2 diabetes
We report the feasibility of [18 F]Canagliflozin PET imaging to determine canagliflozin kidney disposition and SGLT2 occupancy. This suggests the potential of [18 F]Canagliflozin as a tool to visualize and quantify clinically SGLT2 tissue binding.PMID:36897753 | DOI:10.1002/cpt.2886 (Source: Clinical Pharmacology and Therapeutics)
Source: Clinical Pharmacology and Therapeutics - March 10, 2023 Category: Drugs & Pharmacology Authors: Sjoukje van der Hoek Antoon Tm Willemsen Ton Visser Andre Heeres Douwe J Mulder Reinoud Ph Bokkers Riemer Hja Slart Philip H Elsinga Hiddo Jl Heerspink Jasper Stevens Source Type: research
Feasibility study to assess canagliflozin distribution and sodium-glucose co-transporter 2 occupancy using [ < sup > 18 < /sup > F]Canagliflozin in patients with type 2 diabetes
We report the feasibility of [18 F]Canagliflozin PET imaging to determine canagliflozin kidney disposition and SGLT2 occupancy. This suggests the potential of [18 F]Canagliflozin as a tool to visualize and quantify clinically SGLT2 tissue binding.PMID:36897753 | DOI:10.1002/cpt.2886 (Source: Clinical Pharmacology and Therapeutics)
Source: Clinical Pharmacology and Therapeutics - March 10, 2023 Category: Drugs & Pharmacology Authors: Sjoukje van der Hoek Antoon Tm Willemsen Ton Visser Andre Heeres Douwe J Mulder Reinoud Ph Bokkers Riemer Hja Slart Philip H Elsinga Hiddo Jl Heerspink Jasper Stevens Source Type: research
